ABSTRACT
Conclusion:
We assume that adjuvant therapy should be given in high-risk patients operated for gGIST in the presence of necrosis and high Ki-67.
Results:
Seventeen (50%) patients were male. The median age was 64 years. According to Miettinen Risk Scores, seven patients were (20.6%) in very low-risk group, five (14.7%) in low-risk group, 17 (50%) in moderate-risk group, and five (14.7%) patients were in high-risk group. Adjuvant therapy was given in 11 (32.4%) patients. The 5- and 10-year DFS rates were same as 79.2%. The 5- and 10-year overall survival rates were 90.9% and 85.6%, respectively. In multivariate analysis, presence of necrosis [Hazard rate (HR)=9.5], being in high-risk group (HR=27.2), Ki-67 (HR=1.03), and receiving adjuvant therapy (HR=0.51) were factors affecting DFS.
Methods:
This was a retrospective analysis of 34 patients with resectable gGIST who were followed up and treated at the oncology clinic between 2008 and 2019. Patients with metastatic disease and non-gastric disease and those aged <18 years were excluded.
Aim:
Gastrointestinal stromal tumors (GISTs) are extremely rare. In this study, we aimed to analyze the factors affecting disease-free survival (DFS) in patients operated for non-metastatic gastric GIST (gGIST).
References
1
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65.
2
Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
3
Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015;24:298-302.
4
Chandrasekhara V, Ginsberg GG. Endoscopic management of gastrointestinal stromal tumors. Curr Gastroenterol Rep 2011;13:532-9.
5
Rubin BP, Fletcher JA, Fletcher CDM. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol 2000;8:5-10.
6
Zhong Y, Deng M, Liu B, Chen C, Li M, Xu R. Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location. Intractable Rare Dis Res 2013;2:11-7.
7
Sakin A, Can O, Arici S, Yasar N, Geredeli C, Demir C, et al. Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors. J Surg Res 2019;241:170-7.
8
Yang Z, Feng X, Zhang P, et al. Clinicopathological features and prognosis of 276 cases of primary small (</= 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review. Surg Endosc 2019;33:2982-90.
9
Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-93.
10
Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
11
Jin Y, Lu Z, Cao K, et al. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther 2010;9:211-23.
12
Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-10.
13
Seker M, Sevinc A, Yildiz R, et al. Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey. Hepatogastroenterology 2013;60:768-75.
14
Selcukbiricik F, Yalçın S, Tural D, et al. Gastrointestinal stromal tumors in Turkey: experiences from 3 centers. Onkologie 2013;36:18-24.
15
Al-Kalaawy M, El-Zohairy MA, Mostafa A, Al-Kalaawy A, El-Sebae H. Gastrointestinal stromal tumors (GISTs), 10-year experience: patterns of failure and prognostic factors for survival of 127 patients. J Egypt Natl Canc Inst 2012;24:31-9.
16
Aghdassi A, Christoph A, Dombrowski F, et al. Gastrointestinal Stromal Tumors: Clinical Symptoms, Location, Metastasis Formation, and Associated Malignancies in a Single Center Retrospective Study. Dig Dis 2018;36:337-45.
17
Stanek M, Pisarska M, Budzynska D, et al. Gastric gastrointestinal stromal tumors: clinical features and short- and long-term outcomes of laparoscopic resection. Wideochir Inne Tech Maloinwazyjne 2019;14:176-81.
18
Wang M, Xue A, Yuan W, et al. Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs). J Gastrointest Surg 2019;23:2136-43.
19
Li J, Zhang H, Chen Z, Su K. Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population. Int J Clin Exp Pathol 2015;8:15969-76.
20
Segales-Rojas P, Lino-Silva LS, Aguilar-Cruz E, Salcedo-Hernandez RA. Association of ki67 Index with Recurrence in Gastrointestinal Stromal Tumors. J Gastrointest Cancer 2018;49:543-7.
21
Hatipoglu E, Demiryas S. Gastrointestinal stromal tumors: 16 years’ experience within a university hospital. Rev Esp Enferm Dig 2018;110:358-64.
22
Bertin M, Angriman I, Scarpa M, et al. Prognosis of gastrointestinal stromal tumors. Hepatogastroenterology 2007;54:124-8.
23
Schizas D, Bagias G, Kanavidis P, et al. Prognostic factors affecting mortality in patients with esophageal GISTs. J BUON 2020;25:497-507.
24
Yi M, Xia L, Zhou Y, et al. Prognostic value of tumor necrosis in gastrointestinal stromal tumor: A meta-analysis. Medicine (Baltimore) 2019;98:e15338.
25
Huang Y, Zhao R, Cui Y, et al. Effect of Gastrointestinal Bleeding on Gastrointestinal Stromal Tumor Patients: A Retrospective Cohort Study. Med Sci Monit 2018;24:363-9.
26
Yang ML, Wang JC, Zou WB, Yao DK. Clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients. Oncol Lett 2018;16:4905-14.
27
Pyo JS, Kang G, Sohn JH. Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis. Int J Biol Markers 2016;31:204-10.
28
Wang H, Chen P, Liu XX, et al. Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors. World J Surg Oncol 2014;12:89.
29
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
30
Casali PG, Le Cesne A, Poveda Velasco A, et al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 2015;33:4276-83.